July 28 (Reuters) - AstraZeneca Plc said on Tuesday
its diabetes drug Farxiga met the main goal in a late-stage
trial testing the drug's effectiveness in treating patients with
chronic kidney disease.
The trial also met all of its secondary goals in chronic
kidney disease patients with and without type-2 diabetes".
(Reporting by Aakash Jagadeesh Babu in Bengaluru: Editing by
Bernard Orr)